A5101899109- Endometrial and Cervical Cancer Treatments
- Glioma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Histone Deacetylase Inhibitors Research
- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Chromatin Remodeling and Cancer
- Pancreatic and Hepatic Oncology Research
- Ear and Head Tumors
- Bladder and Urothelial Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Lung Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cervical Cancer and HPV Research
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Surgical Oncology
- Ocular Oncology and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiation Therapy and Dosimetry
- Endometriosis Research and Treatment
- Bone Tumor Diagnosis and Treatments
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
WellStar Health System
2024
Emory University
2018-2022
UPMC Hillman Cancer Center
2014-2017
University of Pittsburgh
2014-2015
Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, the potential to enhance chemoradiation. The purpose of this clinical trial was assess efficacy combining belinostat standard-of-care therapy. Thirteen patients were enrolled in each control cohorts. cohort given regimen (500–750 mg/m2 1×/day × 5 days) every three weeks (weeks 0, 3, 6 RT). All received temozolomide radiation...
Purpose: The aim is to provide a practical approach the planning technique and evaluation of plan quality for multi-lesion, single-isocenter stereotactic ablative radiotherapy (SABR) lung. Methods Materials: Eleven patients with 2 or more lung lesions underwent VMAT radiosurgery IMRS. All plans were normalized target maximum dose. For each plan, all targets treated same Plan conformity dose gradient maximized control tuning structures surrounding targets. comparison, multi-isocenter...
Because of the rarity uterine clear cell carcinoma (UCCC), a National Cancer Data Base analysis was conducted to evaluate practice patterns and implications adjuvant therapy.The queried for UCCC patients diagnosed from 1998 2011. Patients receiving neoadjuvant therapy, lacking surgical staging, or having follow-up time shorter than 6 months were excluded. Factors associated with utilization assessed using logistic regression. To define probability chemotherapy radiotherapy (CT + RT),...
e23508 Background: Chondrosarcoma is a rare malignant tumor of bones. Reports its outcomes and prognostic factors are scarce. Methods: The NCDB was queried for patients diagnosed 2004-2013 with chondrosarcoma. Descriptive statistics were generated categorical variables. Means standard deviations numeric Distributions overall survival (OS) estimated using Kaplan-Meier method. Univariate Cox proportional hazards models OS applied. Results: 865 included, 548 males (63.4%) 317 females (36.6%)....
Background: Molecular imaging is increasingly used to guide prostate cancer decisions and treatment planning. The specific aim was evaluate the role of fluciclovine (18F) PET/CT [PET] in improving control over conventional for post-prostatectomy radiotherapy.Methods: Patients with detectable PSA negative were randomized radiotherapy directed by (Arm 1) vs imaging+PET 2). setting an academic medical center community affiliates. In Arm 2, rigidly determined PET, which also target delineation....
SummaryIn this article, we describe the first known case in which high-resolution ultrasound was used to guide treatment iridium-based high-dose rate surface brachytherapy for basal cell carcinoma. The lesion located on of patient's nose, and patient also had advanced multiple myeloma. This particular modality intended reduce scatter dose bone marrow as well lower risk epistaxis. Excellent response achieved. In
Abstract INTRODUCTION Glioblastoma (GBM) is highly aggressive with poor prognosis. Belinostat a histone deacetylase inhibitor blood–brain barrier permeability that has anti-GBM activity and may enhance effects of chemoradiation. Our institution conducted clinical trial evaluating efficacy belinostat standard-of-care therapy for GBMs. METHODS 13 14 patients were enrolled into cohort 1 (c1, control) or 2 (c2, belinostat) 12 in each group sufficient follow-up MRIs recurrence analysis. All...
Abstract PurposeGlioblastoma (GBM) is highly aggressive with poor prognosis. Belinostat a histone deacetylase inhibitor blood–brain barrier permeability, anti-GBM activity, and potential to enhance chemoradiation. The purpose of this clinical trial was assess the efficacy combining belinostat standard-of-care therapy for GBMs. Methods13 patients were enrolled in each control cohorts. cohort given regimen (500-750 mg/m 2 1x/day x 5 days) every 3 weeks (weeks 0, 3, 6 RT). All received...
Abstract PURPOSE Glioblastomas (GBMs) are highly aggressive brain tumors with poor prognosis. Belinostat is a histone deacetylase inhibitor blood–brain barrier permeability, anti-GBM activity, and potential to enhance chemoradiation. This clinical trial sought determine tolerable dose of concurrent belinostat assess the efficacy combining this drug standard-of-care therapy. METHODS 13 patients each were enrolled in control cohorts. The cohort was given regimen (500-750mg/m2 1x/day x 5 days)...